These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 16423595)
1. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. Tsai MH; Huang YC; Yen MH; Li CC; Chiu CH; Lin PY; Lin TY; Chang LY J Pediatr; 2006 Jan; 148(1):38-43. PubMed ID: 16423595 [TBL] [Abstract][Full Text] [Related]
2. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. Tse SM; Silverman ED; McCrindle BW; Yeung RS J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960 [TBL] [Abstract][Full Text] [Related]
3. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin. Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785 [TBL] [Abstract][Full Text] [Related]
4. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617 [TBL] [Abstract][Full Text] [Related]
5. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868 [TBL] [Abstract][Full Text] [Related]
6. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Kawasaki disease using locally product intravenous immunoglobulin. Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163 [TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease. Manlhiot C; Yeung RS; Chahal N; McCrindle BW Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528 [TBL] [Abstract][Full Text] [Related]
9. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study]. DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF; Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869 [TBL] [Abstract][Full Text] [Related]
10. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Durongpisitkul K; Gururaj VJ; Park JM; Martin CF Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221 [TBL] [Abstract][Full Text] [Related]
11. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms. Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995 [TBL] [Abstract][Full Text] [Related]
12. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Lee TJ; Kim KH; Chun JK; Kim DS Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590 [TBL] [Abstract][Full Text] [Related]
13. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease. Arj-ong S; Chotivitayatarakorn P; Lertsapcharoen P; Khongphatthanayothin A; Thisyakorn C J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S179-88. PubMed ID: 12929987 [TBL] [Abstract][Full Text] [Related]
14. Predicting IVIG resistance in UK Kawasaki disease. Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241 [TBL] [Abstract][Full Text] [Related]
17. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease. Wang CL; Wu YT; Lee CJ; Liu HC; Huang LT; Yang KD J Pediatr; 2002 Oct; 141(4):560-5. PubMed ID: 12378198 [TBL] [Abstract][Full Text] [Related]
18. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. Sundel RP; Baker AL; Fulton DR; Newburger JW J Pediatr; 2003 Jun; 142(6):611-6. PubMed ID: 12838187 [TBL] [Abstract][Full Text] [Related]
19. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Kuo HC; Yang KD; Liang CD; Bong CN; Yu HR; Wang L; Wang CL Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314 [TBL] [Abstract][Full Text] [Related]
20. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]